Toshie Iijima

Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease

Masanori Shimizu, Kunihiro Suzuki, Kanako Kato et al. · Diabetes Obesity and Metabolism · 2018 · 364 citations

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

Teruo Jojima, Takanori Tomotsune, Toshie Iijima et al. · Diabetology & Metabolic Syndrome · 2016 · 197 citations · Full text

The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma

Teruo Jojima, Sho Wakamatsu, Masato Kase et al. · International Journal of Molecular Sciences · 2019 · 120 citations · Full text

Immunology, Pathology, Canagliflozin Group +21

Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice

Teruo Jojima, Kohsuke Uchida, Kazumi Akimoto et al. · Atherosclerosis · 2017 · 101 citations

Inflammation, Glp-1 Receptor Agonist, Apoe Deficient Mice +11

Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase‐4 in patients with type 2 diabetes and non‐alcoholic fatty liver disease

Yoshimasa Aso, Kanako Kato, Shintaro Sakurai et al. · International Journal of Clinical Practice · 2019 · 97 citations · Full text